Caveolins and heart diseases

Advances in Experimental Medicine and Biology

Volumn 729, Issue , 2012, Pages 145-156

  Panneerselvam, Mathivadhani ^a   Patel, Hemal H ^a   Roth, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; MESSENGER RNA;

ARTICLE; ATHEROSCLEROSIS; CAVEOLA; CAVEOLIN 3 GENE; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY;

ANIMALS; CARDIOVASCULAR SYSTEM; CAVEOLINS; HEART DISEASES; HUMANS;

EID: 84859795941     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-1222-9_10     Document Type: Article

References (93)

1. Palade GE. Anelectronmicroscope study of themitochondrial stmcture. J Histochem Cytochem 1953; 1:188-211.
2. Razani B, Woodman SE, Lisanti MP. Caveolae: From cell biology to animal physiology. Pharmacol Rev 2002; 54:43 1-467.
3. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid rafi microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007; 8: 128-140.
4. Patel HH, Insel PA. Lipid rafis and caveolae and their role in compartmentation ofredox signaling. Antioxid Redox Signal 2009; 11:1357-1372.
5. Cohen AW, Combs TP, Scherer PE et al. Role of caveolin and caveolae in insulin signaling and diabetes. Am J Physiol Endocrinol Metab 2003; 285:E1 151-1160.
6. van Deurs B, Roepstorff K, Hommelgaard AM et aL Caveolae: Anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 2003; 13:92-100.
7. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8:185-194.
8. Patel HH, Munay F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol 2008; 48:359-39 1.
9. SotgiaF,LeeJK,Das K et al. Caveolin-3 directly interacts with the C-terminal tail of beta-dystroglycaii Identification of a central WW-like domain within caveolin family members. J Biol Chem 2000; 275:38048-38058.
10. Scherer PE, Lisanti MP. Association of phosphofructokinase-M with caveolin-3 in differentiated skeletal myotubes. Dynamic regulation by extracellular glucose and intracellular metabolites. J Biol Chem 1997; 272:20698-20705.
11. Hernandez-Deviez DJ, Martin S, Laval SH et al. Abenant dysferlin trafucking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum Mol Genet 2006; 15:129-142.
12. Cho WJ, Chow AK, Schulz Ret al. Caveolin-i exists and may function in cardiomyocytes. Can J Physiol Pharmacol 88:73-76.
13. Patel HH, Tsutsumi YM, Head BP et al. Mechanisms of cardiac protection from ischemia/reperfttsion injury: A role for caveolae and caveolin-i. FASEB J 2007; 21:1565-1574.
14. Robenek H, Weissen-Plenz G, Severs NJ. Freeze-fracture replica immunolabelling reveals caveolin-i in the human cardiomyocyte plasma membrane. J Cell Mol Med 2008; 12:25 19-2521.
15. Park DS, Cohen AW, Frank PG et al. Caveolin-1 null (-/-) mice show dramatic reductions in life span. Biochemistry 2003; 42:15124-15131.
16. Hnasko R, Lisanti MP. The biology of caveolae: Lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003; 3:445-464.
17. Li WP, Liu P, Pilcher BK et al. Cell-specific targeting of caveolin-ito caveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci 2001; 114:1397-1408.
18. Sowa G, Xie L, Xu Let al. Serine 23 and 36 phosphorylation of caveolin-2 is differentially regulated by targeting to lipid rafi caveolae and in mitotic endothelial cells. Biochemistry 2008; 47:101-111.
19. CapozzaF, CohenAW, Cheung MW et al. Muscle-specific interactionof caveolinisoforms: Differential complex formation between caveolins infibroblastic vs muscle cells. Am J Physiol Cell Physiol 2005; 288:C677-691.
20. Rybin VO, Grabham PW, Elouardighi H et al. Caveolae-associated proteins in cardiomyocytes: Caveolin-2 expression and interactions with caveolin-3. Am J Physiol Heart Circ Physiol 2003; 285:H325-332.
21. Sowa O, Pypaert M, Fulton D et al. The phosphorylation of caveolin-2 on serines 23 and 36 modulates caveolin-i-dependent caveolae formation. Proc Natl Acad Sci USA 2003; 100:6511-6516.
22. Lee H, Park DS, Wang XB et al. Src-induced phosphorylation of caveolin-2 on tyrosine 19. Phospho-caveolin-2 (Tyr(P)19) is localized near focal adhesions, remains associated with lipid rafis caveolae, but no longer forms a high molecular mass hetero-oligomer with caveolin-i. J Biol Chem 2002; 277:34556-34567.
23. Razani B, Wang XB, Engelman JA et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 2002; 22:2329-23 44.
24. Minetti C, Bado M, Broda P et al. Impairment ofcaveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am J Pathol 2002; 160:265-270.
25. Galbiati F, Engelman JA, Volonte D et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex and t-tubule abnormalities. J Biol Chem 2001; 276:21425-21433.
26. Lin E, Hung VH, Kashihara H et al. Distribution patterns of the Na-Ca2 exchanger and caveolin-3 in developing rabbit cardiomyocytes. Cell Calcium 2009; 45:369-383.
27. Ratajczak P, Damy T, Heymes C et al. Caveolin-i and -3 dissociations from caveolae to cytosol in the heart during aging and afler myocardial infarction in rat. Cardiovasc Res 2003; 57:358-369.
28. RatajczakP, Oliviero P, Marotte F et al. Expressionand localization of caveolins during postnatal development in rat heart: Implication of thyroid hormone. J Appl Physiol 2005; 99:244-251.
29. Capozza F, Combs TP, Cohen AW et al. Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. Am J Physiol Cell Physiol 2005; 288:C1317-1331.
30. Woodman SE, Park DS, Cohen AW et al. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42 44 MAPK cascade. J Biol Chem 2002; 277:38988-38997.
31. KogaA, OkaN, Kikuchi T et al. Adenovims-mediated overexpression of caveolin-3 inhibits rat cardiomyocyte hypertrophy. Hypertension 2003; 42:213-219.
32. HorikawaYT, PatelHH,Tsutsumi YM et al. Caveolin-3 expression and caveolae are required for isoflurane-induced cardiac protection from hypoxia and ischemia/reperfusion injury. J Mol Cell Cardiol 2008; 44:123-130.
33. Tsutsumi YM,Horikawa YT,Jemtgs MM et al. Cardiac-specific overexpressionof caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation 2008; 118:1979-1988.
34. Galbiati F, Volonte D, Chu JB et al. Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. Proc Natl Acad Sci USA 2000; 97:9689-9694.
35. Aravamudan B, Volonte D, Ramani Ret al. Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype. Hum Mol Genet 2003; 12:2777-2788.
36. Mathew R, Huang J, Shah M et al. Disruption of endothelial-cell caveolin-lalpha rafi scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 2004; 110:1499-1506.
37. Patel HH, Zhang S, Murray F et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute tothe pathophysiology of idiopathicpulmonary arterial hypertension. FASEB J2007; 21:2970-2979.
38. Swaney JS, Patel HH, Yokoyama U et al. Focal adhesions in (myo)fibroblasts scaffold adenylyl cyclase with phosphorylated caveolin. J Biol Chem 2006; 281:17173-17179.
39. Patel HH, Head BP, Petersen HN et al. Protection of adult rat cardiac myocytes from ischemic cell death: Role of caveolar micro domains anddelta-opioidreceptors. Am J Physiol Heart Circ Physiol 2006; 291 :H344-350.
40. Darblade B, Caillaud D, Poirot M et al. Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta. Cardiovasc Res 2001; 50:566-576.
41. Drab M, Verkade P, Elger M et al. Loss of caveolae, vascular dysfunction and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293 :2449-245 2.
42. Razani B, Engelman JA, Wang XB et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276:38121-38138.
43. Zhao YY, Liu Y, Stan RV et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 2002; 99:11375-11380.
44. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 2006; 69:788-797.
45. Ohsawa Y, Toko H, Katsura M et al. Overexpression of P1O4L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy v ith enhanced contractility in association ith increased endothelial nitric oxide synthase activity. Hum Mol Genet 2004; 13:151-157.
46. Dhillon B, Badiwala MV, Li SH et al. Caveolin: A key target for modulating nitric oxide availability in health and disease. Mol Cell Biochem 2003; 247:101-109.
47. Brouet A, Sonveaux P, Dessy C et al. Hsp9O and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001; 89:866-873.
48. Frank PO, Lee H, Park DS et al. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24:98-105.
49. Feron O, Kelly RA. The caveolar paradox: Suppressing, inducing and terminating eNOS signaling. Circ Res 2001; 88:129-13 1.
50. Ostrom RS. New determinants of receptor-effector coupling: Trafucking and compartmentation in membrane microdomains. Mol Pharmacol 2002; 61:473-476.
51. Folco EJ, Liu OX, Koren O. Caveolin-3 and 5AP97 form a scaffolding protein complex that regulates the voltage-gated potassium channel Kvl.5. Am J Physiol Heart Circ Physiol 2004; 287:H681-690.
52. Balijepalli RC, Foell JD, Hall DD et al. Localization of cardiac L-type Ca(2+) channels to a caveolar macromolecular signaling complex is required for beta(2)-adrenergic regulation. Proc Natl Acad Sci USA 2006; 103 :7500-7505.
53. Martens JR, Sakamoto N, Sullivan SA et al. Isoform-specific localization of voltage-gated K+ channels to distinct lipid rafi populations. Targeting of Kvl.5 to caveolae. J Biol Chem 2001; 276:8409-8414.
54. Wang H, Haas M, Liang M et al. Ouabain assembles signaling cascades through the caveolar Na+ K+-ATPase. J Biol Chem 2004; 279:17250-17259.
55. Camors E, Charue D, Trouve P et al. Association of annexin AS with Na+ Ca2+ exchanger and caveolin-3 in nonfailing and failing human heart. J Mol Cell Cardiol 2006; 40:47-5 5.
56. Catteruccia M, Sanna T, Santorelli FM et al. Rippling muscle disease and cardiomyopathy associated with a mutation in the CAV3 gene. Neuromuscul Disord 2009; 19:779-7 83.
57. Vatta M, Ackerman MJ, Ye B et al. Mutant cavenlin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006; 114:2104-2112.
58. Napolitano C, Rivohal, Priori SO. Cardiac sodium channel diseases. Clin Chem Lab Med 2003; 41:439-444.
59. Cronk LB, Ye B, Kaku T et al. Novel mechanism for sudden infant death syndrome: Persistent late sodium cunent secondary to mutations in caveolin-3. Heart Rhythm 2007; 4:161-166.
60. Anselmi A, Gaudino M, Baldi Aet al. Role ofapoptosis in pressure-overload cardiomyopathy. J Cardiovasc Med (Hagerstown) 2008; 9:227-232.
61. Bogaard HJ, Abe K, Vonk Noordegraaf Aet al. The right ventricle under pressure: Cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009; 135:794-804.
62. Stanton T, Ingul CB, Hare JL et al. Interaction of lefi ventricular geometry and myocardial ischemia in the response of myocardial deformation to stress. Am J Cardiol 2009; 104:897-903.
63. Swynghedauw B, Delcayre C, Samuel JL et al. Molecular mechanisms in evolutionary cardiology failure. Ann NY Acad Sci 2010; 1188:58-67.
64. Kimura TE, Jin J, Zi M et al. Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res 2010; 106:961-970.
65. Augustus AS, Buchanan J, Gutman E et al. Hearts lacking caveolin-1 develop hypertrophy with normal cardiac substrate metabolism. Cell Cycle 2008; 7:2509-2518.
66. Cohen AW, Park DS, Woodman SE et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivationofp42 44 MAPkinase incardiacfibroblasts. Am J Physiol Cell Physiol 2003; 284:C457-474.
67. Dc SouzaAP, CohenAW, Park DS et al. MRimaging of caveolin gene-specific alterations inright ventricular wall thickness. Magn Reson Imaging 2005; 23 :61-68.
68. Jasmin JF, Mercier I, Dupuis J et al. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006; 114:912-920.
69. Fujita T. Toya Y. Iwatsubo K et al. Accumulation of molecules involved in alphal-adrenergic signal within caveolae: Caveolin expression and the development of cardiac hypertrophy. Cardiovasc Res 2001; 51:709-716.
70. Krajewska WM, Maslowska I. Caveolins: Structure and function in signal transduction. Cell Mol Biol Left 2004; 9:195-220.
71. Jeong K, Kwon H, Mm C et al. Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts. Exp Mol Med 2009; 41:226-235.
72. Park DS, Woodman SE, Schubert Wet al. Caveolin-1 3 double-knockout mice are viable, but lack both muscle and nonmuscle caveolae and develop a severecardiomyopathic phenotype. Am J Pathol 2002; 160:2207-2217.
73. Aoyagi T, Ishikawa Y, Oshikawa H et al. Caveolin-3 is up-regulated in the physiological lefi ventricular hypertrophy induced by voluntary exercise training in rats. J Sports Science Med 2002; 1:141-146.
74. Giusti B, Marini M, Rossi L et al. Gene expression profile of rat lefi ventricles reveals persisting changes following chronic mild exercise protocol: Implications for cardioprotection. BMC Genomics 2009; 10:342.
75. Hayashi T, Arimura T, Ueda K et al. Identification and fuinctional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2004; 313:178-184.
76. Kikuchi T, Oka N, Koga A et al. Behavior of caveolae and caveolin-3 during the development of myocyte hypertrophy. J Cardiovasc Pharmacol 2005; 45 :204-210.
77. Ruiz-Hurtado U, Fernandez-Velasco M, Mourelle M et al. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 2007; 50:1049-1056.
78. Piech A, Massart PE, Dessy C et al. Decreased expression of myocardial eNOS and caveolin in dogs with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2002; 282:H219-231.
79. Damy I, Ratajczak P, Shah AM et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004; 363:1365-1367.
80. Hare JM, Lofihouse RA, Juang GJ et al. Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. Circ Res 2000; 86:1085-1092.
81. Head BP, Patel HH, Roth DM et al. Microtubules and actin microfilaments regulate lipid rafi caveolae localization of adenylyl cyclase signaling components. J Biol Chem 2006; 281:26391-26399.
82. Nikolaev VO, Moshlcov A, Lyon AR et al. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327:1653-1657.
83. Muny CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124-1136.
84. Hausenloy DJ, Tsang A, Yellon DM. The reperfitsion injury salvage kinase pathway: A common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005; 15:69-75.
85. Tong H, Imahashi K, Steenbergen C et al. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ Res 2002; 90:377-379.
86. Hausenloy DJ, Tsang A, Mocanu MM et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfiision. Am J Physiol Heart Circ Physiol 2005; 288:H971-976.
87. Vinten-Johansen J, Zhao ZQ, Jiang R et al. Preconditioning and postconditioning: Innate cardioprotection from ischemia-reperfusion injury. J Appi Physiol 2007; 103:1441-1448.
88. Peart TN, Headrick JP. Clinical cardioprotection and the value of conditioning responses. Am J Physiol Heart Circ Physiol 2009; 296:H1705-1720.
89. Tsang A, Hausenloy DJ, Mocanu MM et al. Postconditioning: A form of"modified reperfiision" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004; 95 :230-232.
90. Young LH, Ikeda Y, Lefer AM. Caveolin-1 peptide exerts cardioprotective effects in myocardial ischemia-reperfusion via nitric oxide mechanism. Am J Physiol Heartcirc Physiol 2001; 280:H2449-H2495.
91. Ballard-Crofi C, Locklar AC, Kristo Octal. Regional myocardial ischemia induced activation of MAPKs is associated with subcellular redistribution of caveolin and cholesterol. Am J Physiol Heart Circ Physiol 2006; 291 :H658-667.
92. Der P, Cui J, Das DK. Role of lipid rafis in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts. J Mol Cell Cardiol 2006; 40:313-320.
93. Koneru S, Penumathsa SV, ThirunavukkarasuM et al. Redox regulation of ischemicpre conditioning is mediated by the differential activation of caveolins and their association with eNOS and OLUT-4. Am J Physiol Heart Circ Physiol 2007; 292:H2060-2072.